Edition:
India

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.56USD
12:45am IST
Change (% chg)

$0.13 (+3.79%)
Prev Close
$3.43
Open
$3.43
Day's High
$3.57
Day's Low
$3.43
Volume
36,977
Avg. Vol
190,321
52-wk High
$5.71
52-wk Low
$1.07

Chart for

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $171.64
Shares Outstanding(Mil.): 36.99
Dividend: --
Yield (%): --

Financials

BRIEF-Verastem reports Q3 loss per share of $0.61

* Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​

* Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA

31 Oct 2017

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

17 Oct 2017

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

06 Sep 2017

UPDATE 2-Verastem's blood cancer drug succeeds in late-stage trial

* Drug could rake in >$400 mln within 5 yrs of launch -analyst

06 Sep 2017

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

06 Sep 2017

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

06 Sep 2017

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

06 Sep 2017

BRIEF-Verastem announces positive top-line data from the pivotal phase 3 Duo study

* Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

06 Sep 2017

Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

06 Sep 2017

Earnings vs. Estimates